Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is that ...

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is ...

So JOURNAVX is a NaV1.8 inhibitor ... We have initiated these conversations with the FDA, but we haven't concluded them. We're going to have our end of Phase 2 meeting this summer, and I expect ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Journavx, a sodium-channel inhibitor that blocks pain signals, is effective but non-addictive, and is the first new class of pain medication approved by the US Food and Drug Administration (FDA ...